R&D channel feed – Endpoints News

R&D channel feed

Bayer, Orion prostate cancer drug delays spread of disease in PhIII, but can it make a mark in a crowded market?

7 years ago

Fresh from a $72M raise, Jeff Aronin's new lead rare disease drug is flagged as a failure

7 years ago

Nav1.7 analgesic failures stack up as Biogen abandons vixotrigine after latest setback

7 years ago

Amid repeated stumbles, Pfizer and Eli Lilly tout their anti-NGF pain drug tanezumab — but questions linger

7 years ago

UCB, Biogen admit defeat in PhII lupus trial, adding to a string of late-stage failures in the field

7 years ago

Enterome fortifies Takeda relationship with $50M upfront to co-develop Crohn's drug

7 years ago

Rattled by setbacks, Celgene turns to ex-Merck R&D star Alise Reicin to repair its damaged development rep

7 years ago

#ESMO18: Novartis claims a key win in breast cancer with PI3K drug alpelisib

7 years ago

Winners and losers at #ESMO18

7 years ago

One of Hal Barron's top drug prospects at GSK flunks a PhII test for rheumatoid arthritis, flailing in an intensely competitive field

7 years ago

Chipping away at Gilead's HIV empire, GSK's ViiV submits NDA for 2-drug HIV regimen -- playing voucher card for speedy FDA review

7 years ago

Merrimack Pharma’s stock plunges (again) on its latest cancer drug trial flop

7 years ago

#ESMO18: Crowned with a breakthrough title, Clovis takes an early lead as it races for a fast OK for Rubraca in prostate cancer

7 years ago

Merck previews an early hit with Keytruda combo for kidney cancer, putting more pressure on rival Bristol-Myers

7 years ago

Proteostasis shares zoom north as their cystic fibrosis doublet causes a stir in small study -- triggering an online brawl

7 years ago

Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T

7 years ago

FDA slaps down Novartis' blockbuster pitch for canakinumab — so what went wrong?

7 years ago

J&J takes a $630M asset hit on the books, shuttering PhIIb trials as its $1.75B RSV drug teeters on the brink

7 years ago

Eiger chalks up one win, one loss between a pair of PhII rare disease drugs, reshuffling priorities

7 years ago

Merck KGaA looks to boost drug R&D alliances as the CFO crunches the numbers on development costs

7 years ago

FDA lists 205 molecular targets for pediatric cancer research

7 years ago

Roche torches a mountain of biobucks, sweeping out a roster of drugs in the latest pipeline cleanup

7 years ago

Regeneron, Sanofi talk up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII

7 years ago

Pharnext rare disease drug scores in late-stage study, teeing up applications at the FDA and EMA

7 years ago

First page Previous page 260 261 262263264 265 266 Next page Last page